Efficacy of Sumatriptan With Naprosyn in Migraine With Aura - Full Text View

Sponsor:	Dent Neurologic Institute
Information provided by:	Dent Neurologic Institute
ClinicalTrials.gov Identifier:	NCT00893594

Purpose

This is a double-blinded placebo study, examining the efficacy of Sumatriptan with Naprosyn in the treatment of migraine with aura.

Condition	Intervention
Migraine With Aura	Drug: sumatriptan with naprosyn Drug: placebo

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:	A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura

Resource links provided by NLM:

Genetics Home Reference related topics: familial hemiplegic migraine

MedlinePlus related topics: Headache Migraine

Drug Information available for: Naproxen Naproxen sodium Sumatriptan Sumatriptan succinate

U.S. FDA Resources

Further study details as provided by Dent Neurologic Institute:

Primary Outcome Measures:

Primary outcome measure will be comparative percentage of patients pain free at 2 and 4 hours from initiating treatment with placebo vs treatment with Treximet (sumatriptan with naprosyn). [ Time Frame: 2 and 4 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Secondary outcomes will be percentage of patients with pain relief at 2 and 4 hours. [ Time Frame: 2 and 4 hours ] [ Designated as safety issue: No ]

Estimated Enrollment:	30
Study Start Date:	September 2009
Estimated Study Completion Date:	September 2010
Estimated Primary Completion Date:	September 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Placebo Comparator Placebo taken at onset of aura associated with migraine.	Drug: placebo Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
2: Active Comparator Sumatriptan with naprosyn taken at onset of aura associated with migraine.	Drug: sumatriptan with naprosyn Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Subjects must be 18 to 50 years of age, inclusive.
Patients will meet the International Headache Society (IHS) classification criteria for migraine with aura.
Subjects must carry the diagnosis of 1-2 migraine with aura per month for at least three months before study inclusion. and migraine with aura were included in the study
Subjects must have an onset of a visual aura that occurs 15-30 minutes before a migraine headache.
Subjects must be able to understand and complete a migraine diary.
Subjects must be able to distinguish a migraine with aura from other types of headache.
Subjects must be in generally good health as confirmed by medical and medication history, baseline physical and neurological exam and vital signs.
Female subjects must be either a) postmenopausal for one year, b)surgically sterile, c) practicing acceptable birth control for at least one month prior to screening and throughout study, or d) practicing abstinence and agree to continue same throughout study.

Exclusion Criteria:

Subjects who have a significant systemic disease other than migraine that is equally painful or more painful.
Subjects who have other progressive neurological disorders.
Subjects who have more than 8 migraines or 15 headache days per month.
Subjects who have previously taken Treximet and failed due to lack of efficacy or adverse side effects.
Subjects who carry the diagnosis of chronic tension type headache or cluster headache based on the International Headache Society criteria.
Subject should not have received any other investigative drug within 3 months prior to enrollment in the study.
Subject who have the diagnosis of seizure disorder, chronic daily headache, uncontrolled hypertension, cardiovascular disease, history of stroke, basilar or hemiplegic migraine, hepatic disease, or active peptic ulcer disease.
Subjects currently taking or in 3 months prior to study, use of prophylactic migraine medications.
Subjects who have a known allergy to Sumatriptan or Naprosyn.
Subjects who in the opinion of Dr. Mechtler have a condition for which they should not be enrolled in the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00893594

Contacts

Contact: Mary K Betz, MS

716-250-2000

mbetz@dentinstitute.com

Sponsors and Collaborators

Dent Neurologic Institute

Investigators

Principal Investigator:

Laszlo L Mechtler, MD

Dent Neurologic Institute

More Information

No publications provided

Responsible Party:	Dent Neurologic Institute ( Laszlo Mechtler, MD )
Study ID Numbers:	113010
Study First Received:	May 4, 2009
Last Updated:	May 5, 2009
ClinicalTrials.gov Identifier:	NCT00893594 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Dent Neurologic Institute:

migraine
migraine with aura
headache

Additional relevant MeSH terms:

Serotonin Agonists
Anti-Inflammatory Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Headache Disorders, Primary
Brain Diseases
Gout Suppressants
Headache Disorders
Sensory System Agents
Migraine Disorders
Therapeutic Uses
Vasoconstrictor Agents
Anti-Inflammatory Agents, Non-Steroidal
Migraine with Aura

Analgesics
Naproxen
Nervous System Diseases
Cyclooxygenase Inhibitors
Central Nervous System Diseases
Enzyme Inhibitors
Cardiovascular Agents
Pharmacologic Actions
Sumatriptan
Serotonin Agents
Analgesics, Non-Narcotic
Peripheral Nervous System Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 09, 2010